SEC Form 4 · accession 0000911916-16-000695
CoLucid Pharmaceuticals, Inc. · CLCD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Bernice Kuca
Officer — Head,Clin. and Reg. Operations
Period of report
Dec 1, 2016
Accepted (ET)
Dec 1, 2016 · 4:45 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001348649
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2,F3 | Dec 1, 2016 | S | 772 | $35.2202 | D | 40,858 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Securities sold pursuant to a written plan intended to comply with Rule 10b5-1(c)(i) adopted by Ms. Kuca on August 15, 2016. One purpose of the plan is to sell shares of common stock acquired under the CoLucid Pharmaceuticals, Inc. Employee Stock Purchase Plan.
- F2Represents the sale of 772 shares in multiple transactions, ranging in price from $35.00 to $35.525 per share, resulting in a weighted average sale price of $35.2202. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each price within the range.
- F3Includes 4,130 shares acquired under the CoLucid Pharmaceuticals, Inc. Employee Stock Purchase Plan through November 30, 2016.